Blog

Pancreatic cancer staging uses the TNM system, looking at the tumour itself, whether nearby lymph nodes are involved, and whether disease has reached distant organs, with the resulting stages from I through IV deciding what treatment is realistically possible. EUS combined with CT and MRI gives the most accurate staging picture because external scans alone consistently miss small tumours and the kind of subtle nodal involvement that quietly changes the entire treatment plan. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “Staging accuracy in pancreatic cancer is everything because the difference between Stage I resectable disease and Stage III locally advanced disease often comes down to a few millimetres of vascular involvement that CT cannot reliably show, and getting that wrong sends the patient down completely the wrong treatment pathway.” How Is Pancreatic Cancer Staged Using the TNM System? TNM works by combining three measurements into a single picture, and that combined picture decides what’s realistically possible for the patient sitting in front of you. Tumour: T staging looks at size and local invasion with T1 meaning a tumour under 2 cm sitting inside the pancreas while T4 means disease has reached major vessels like the celiac axis or superior mesenteric artery, so the difference between T2 and T4 often decides surgical eligibility even when the actual size on imaging looks similar across the two stages. Nodes: N staging counts how many regional lymph nodes contain cancer with N0 meaning none, N1 meaning 1 to 3 positive, and N2 meaning 4 or more, and EUS-guided FNA biopsy of suspicious nodes gives the kind of accuracy CT-based staging consistently fails to deliver here because size alone never confirms whether a node is actually involved. Metastasis: M staging is binary because either disease has reached distant organs or it hasn’t, but even one small liver lesion or peritoneal deposit moves the patient straight to Stage IV regardless of how favourable the primary tumour and nodes might look in isolation, which is why thorough M assessment matters as much as anything else in the workup. Stages: Stage I means localised and resectable, Stage II means nearby tissue spread but still potentially operable, Stage III means locally advanced with vascular involvement that often closes the surgical door, while Stage IV means metastatic disease where surgery is almost never the answer anyway and management shifts toward systemic treatment. Getting all three components measured accurately at the start changes the entire treatment plan, and specialist in pancreatic cancer treatment uses EUS alongside CT and MRI rather than relying on external imaging that consistently misses what matters. Why Does EUS Matter So Much in Pancreatic Cancer Staging? CT and MRI give the broad anatomical picture, but EUS gets close enough to the tumour to see what those scans miss, and that proximity changes staging decisions in a meaningful percentage of cases. Size: EUS picks up pancreatic tumours under 2 cm that CT regularly misses entirely because the smallest resectable cancers carry the best survival rates and finding them through EUS is often the only way these patients reach surgical consultation while early-stage intervention is still possible. Vessels: Vascular involvement is the single biggest factor in surgical resectability and EUS shows the relationship between tumour and major vessels with millimetre accuracy CT simply cannot replicate, which is why patients who looked unresectable on CT sometimes turn out to be operable after proper EUS staging changes the picture. Nodes: EUS-guided FNA samples suspicious lymph nodes that CT only flags by size, giving real tissue diagnosis rather than radiological guess, and that distinction matters enormously because not every enlarged node is malignant and not every normal-sized node is clean even when the scan looks reassuring at first glance. Tissue: EUS allows fine needle biopsy of the primary tumour itself in the same session as staging providing histological confirmation before any treatment decision gets made, which is critical because pancreatic cancer treatment is too aggressive to start without biopsy proof sitting in the file ready to act on. EUS-based staging consistently changes surgical decisions in patients whose CT staging looked definitive in either direction. Read more on staging to see how staging principles apply across all GI cancers and why the staging investigation drives the treatment plan rather than the other way around. Why choose Dr. Vipulroy Rathod for analyzing the early staging of pancreatic cancer ? Dr. Vipulroy Rathod has spent over 30 years staging pancreatic cancer through EUS, FNA biopsy, and integrated imaging at Fortis Hospital Mulund, catching the small resectable tumours that CT staging missed entirely and clarifying borderline cases where vascular involvement decided whether the patient was operable, and has trained physicians from 35 countries in this specific staging approach. Most patients arrive with a CT staging report and an assumption their disease is one stage when in fact it’s another, and many leave with EUS-corrected staging that opened up surgical options nobody thought were on the table or, equally importantly, ruled out unnecessary surgery in cases where the disease was already further along than CT suggested it was. 📞 Call Now: +91 9820091763 Book your consultation today with one of India’s most experienced specialists for understanding the stages of pancreatic cancer Book Appointment Call now Frequently Asked Questions What is the most accurate staging method for pancreatic cancer? EUS combined with CT and MRI provides the most accurate pancreatic cancer staging, particularly for tumour size, vascular involvement, and nodal disease. Can pancreatic cancer staging change after treatment starts? Yes, restaging is standard practice after neoadjuvant chemotherapy or radiation to assess response and reconsider surgical resectability. What stage of pancreatic cancer is operable? Stage I and II pancreatic cancers are typically resectable, while Stage III locally advanced disease may become resectable after neoadjuvant therapy. Does Stage IV pancreatic cancer mean surgery is not possible? Yes, Stage IV pancreatic cancer with distant metastasis is rarely treated with surgery, and management focuses on systemic chemotherapy and palliative intervention. Reference links- Pancreatic Cancer Staging Guidelines — American Society for

Pancreatic cancer rarely announces itself early because the pancreas sits buried deep behind the stomach and produces almost nothing in the way of obvious symptoms until the disease has already moved past easy treatment, but there are signals worth taking seriously, and they tend to show up as unexplained weight loss, persistent upper abdominal or back pain, new diabetes after 50 with no real reason, painless jaundice, oily stools, and a slow loss of appetite that doesn’t sort itself out. Most patients land at advanced stage simply because nobody connected those signals back to the pancreas in time to do anything useful about them. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “Pancreatic cancer is one of those conditions where the difference between early and late diagnosis is often the difference between treatable disease and palliative care, and most patients arrive late because the early signs are exactly the kind that get attributed to acidity, stress, or age before anyone thinks to investigate properly.” What Are the Early Warning Signs of Pancreatic Cancer? Individually each of these can mean nothing, but when two or three cluster together or run on for weeks without explanation, they start telling a different story. Weight: Losing 4 to 5 kg without changing anything about your eating or activity is one of the most consistent early signals because pancreatic enzyme production gets disrupted long before any other symptom appears, so the body slowly stops absorbing nutrients properly while the patient and their doctor assume it’s just stress or work catching up. Pain: That dull ache in the upper abdomen radiating through to the back, worse after meals or at night, is a classic pancreatic pattern, and patients often spend months getting treated for gastritis or muscle strain before someone finally connects the pain to the actual organ producing it behind the stomach. Diabetes: New diabetes in a non-obese patient over 50 with no metabolic explanation is a recognised early signal because the tumour disrupts insulin-producing tissue, yet most of these cases get filed straight under endocrine disease and the pancreas itself never gets imaged properly. Jaundice: Yellowing of skin and eyes without any cramping pain shows up when a tumour in the head of the pancreas blocks the bile duct, and unlike gallstone jaundice it tends to arrive quietly without the dramatic abdominal pain, which is exactly why patients delay coming in until family members notice the colour change at home. These signals get more serious when two or more cluster together in the same patient over a short window, and a pancreatic cancer treatment specialist investigates that combination properly rather than treating each symptom as a standalone problem. When Should These Signs Trigger Proper Investigation? Not every symptom on this list means cancer, but specific patient profiles need a much lower threshold for investigation than the general population. Family: Patients with a first-degree relative diagnosed with pancreatic cancer carry significantly elevated lifetime risk and should already be on EUS surveillance regardless of symptoms, because finding a small lesion before any signal develops is the entire point of surveillance and waiting for warning signs in this group means waiting too long. BRCA2: Confirmed BRCA2, BRCA1, or PALB2 carriers face meaningfully higher pancreatic cancer risk and benefit from annual EUS surveillance from age 50, and any of the warning signs in this group should trigger imaging within days rather than the wait-and-see approach used for the same symptoms in average-risk patients. Pancreatitis: Patients living with chronic pancreatitis carry elevated background cancer risk and warning signs can easily get attributed to the pancreatitis itself, so any change in pain pattern, new weight loss, or onset of diabetes in this group needs proper EUS investigation rather than dismissal as the underlying disease acting up. Smokers: Long-term smokers carry roughly double the pancreatic cancer risk of non-smokers and warning signs are statistically more likely to actually mean something here, which is why a smoker over 50 with persistent upper abdominal symptoms genuinely deserves proper investigation rather than the standard reassurance most of them get sent home with. A small lesion found early can be treated, while the same disease six months later usually cannot, and that gap is exactly what surveillance and proper investigation are designed to close. Read more on EUS detection to see which symptoms map to which findings on EUS and why the timing of investigation makes such a real difference. Why choose Dr. Vipulroy Rathod for screening early warning signs of pancreatic cancer ? Dr. Vipulroy Rathod has spent over 30 years investigating pancreatic disease through EUS, fine needle aspiration biopsy, and metabolic workup at Fortis Hospital Mulund, finding small pancreatic lesions in patients whose CT scans were called normal and whose symptoms were being managed as something else entirely, and has trained physicians from 35 countries in this exact diagnostic pathway. Most patients arrive having been reassured for months that nothing serious was happening, and many leave with a real diagnosis caught early enough to actually do something about it, which is the entire reason proper investigation matters at this point in the disease course.   Book your consultation today with one of India’s most experienced specialists for hepatitis and liver cancer evaluation. Book Appointment Call now Frequently Asked Questions What is the most common first symptom of pancreatic cancer? Unexplained weight loss combined with vague upper abdominal discomfort is the most common early presentation of pancreatic cancer. Can pancreatic cancer be detected before symptoms start? Yes, EUS surveillance can find small pancreatic lesions in high-risk patients before any symptoms develop. Is new onset diabetes a sign of pancreatic cancer? New diabetes in a non-obese patient over 50 with no metabolic risk factors is a recognised early signal that warrants pancreatic imaging. How is pancreatic cancer diagnosed early? EUS combined with fine needle aspiration biopsy is the most accurate method for early pancreatic cancer detection in symptomatic and high-risk patients. Reference links- Pancreatic Cancer Early Detection Guidelines — American Society for Gastrointestinal Endoscopy

Chronic hepatitis B and hepatitis C are the two biggest infectious causes of liver cancer worldwide, with each virus driving cancer risk through a different mechanism. Hepatitis B can trigger cancer directly by embedding into liver cell DNA even without cirrhosis, while hepatitis C typically raises risk through the cirrhosis pathway where years of inflammation build scarring that eventually sets the stage for malignancy. According to Dr. Vipulroy Rathod, an experienced Gastroenterologist in Mumbai, “The connection between hepatitis and liver cancer is one of the most well-established links in all of medicine, and yet patients with chronic hepatitis still slip through without being told they need regular screening until a tumour shows up and suddenly the conversation shifts from prevention to damage control.” How does hepatitis actually cause liver cancer? Both viruses jack up cancer risk but they get there through completely different back roads which is why you can’t just run the same surveillance playbook for both, and understanding which mechanism is chewing through a particular patient’s liver changes how hard they need watching and what specifically the screening is looking for. Hep B — direct sabotage: This virus doesn’t bother waiting for cirrhosis to roll in before it starts causing problems because it buries itself directly into the DNA of liver cells and can flip the switches that turn a normal cell cancerous from the inside out, which is why hep B patients can grow hepatocellular carcinoma in a liver that looks perfectly clean on every other test and has zero scarring anywhere. Hep C — the long grind: Hep C takes the scenic route to cancer by keeping the liver in a state of constant low-grade warfare where inflammation slowly stacks fibrosis on top of fibrosis over decades until cirrhosis sets in and that wrecked cirrhotic environment is what eventually rolls out the red carpet for cancer to take root. Cell turnover gone wrong: Both viruses force liver cells to die and regenerate faster than they normally would, and that sped-up turnover is basically a lottery where every cell division carries a small chance of a genetic screw-up and the more tickets you buy over decades of chronic infection the higher the odds that one of those screw-ups eventually becomes a cancer. Stacking damage: Patients carrying both viruses at once or either virus paired with years of heavy booze face cancer risk that doesn’t just climb it rockets, because each factor dumps its own damage on top of what the other’s already done and the liver is copping hits from multiple directions with no breathing room to recover between rounds. If chronic hepatitis has already been diagnosed and you want the full picture of what screening and treatment look like, our liver cancer treatment page covers everything from surveillance schedules through intervention options depending on what shows up. Can treating the virus actually bring the cancer risk down? Treating hepatitis absolutely bends the curve but how much risk drops depends heavily on when treatment happens relative to how much damage the liver has already copped, which is why getting treated at the fibrosis stage versus the cirrhosis stage can mean the difference between a patient who mostly dodges cancer risk and one who carries it around for the rest of their life. Hep B antivirals: Squashing the virus with long-term antivirals drops cancer risk dramatically but doesn’t wipe it out completely because the viral DNA that’s already welded itself into liver cell chromosomes stays parked there even when blood tests show the virus as undetectable, meaning hep B patients on treatment still need six-monthly screening because that embedded DNA can still cause havoc years after the virus itself went quiet. Hep C cure: Direct-acting antivirals now knock out hep C in over 95 percent of patients and clearing the virus chops the cancer risk significantly, but patients who already had cirrhosis before getting cured still sit on elevated risk for years afterward because the scarred-up liver environment that cancer loves doesn’t just pack up and leave the moment the virus gets evicted. Earlier is always better: A patient who gets treated before fibrosis digs in has a wildly better long-term outlook than one who gets treated after cirrhosis has already cemented itself, which is the single strongest argument for catching hepatitis early and treating immediately rather than the outdated approach of sitting on your hands and waiting for the liver to start visibly struggling before doing anything. Screening never fully stops: Even patients with undetectable viral loads and successful treatment still need continued surveillance if they had significant fibrosis or cirrhosis when they started therapy, because cancer risk takes years to properly come down and yanking screening away too early is exactly how tumours get missed in people who assumed the worst was behind them. Knowing how the two hepatitis types differ at a fundamental level helps guide which screening approach fits, and our hepatitis B vs hepatitis C blog breaks down the key differences between the two viruses and why the surveillance game plan can’t just be photocopied from one to the other. Why choose Dr. Vipulroy Rathod for hepatitis and liver cancer screening? Dr. Vipulroy Rathod has over 30 years in gastroenterology and hepatology with more than 80,000 endoscopic procedures behind him, and hepatitis-related cancer risk is one of those areas where knowing whether the patient needs watching because of viral DNA buried inside liver cells or because of a cirrhotic landscape that cancer thrives in changes the entire surveillance setup, and a gastroenterologist who treats both situations as identical is missing a distinction that directly affects how often imaging happens and what it’s actually hunting for. What patients get here is hepatitis management that doesn’t just treat the virus and dust its hands off but keeps the cancer surveillance running for as long as the risk stays elevated, because clearing the bug or beating it down with antivirals is only half the job and the other half is making sure the liver doesn’t

Liver cancer doesn’t strike randomly. It overwhelmingly develops in people who already have an underlying liver condition, with chronic hepatitis B or C, cirrhosis from any cause, and longstanding fatty liver disease accounting for the vast majority of cases. Knowing whether you carry these risk factors is what decides whether you need active screening or can safely skip it. According to Dr. Vipulroy Rathod, an experienced Gastroenterologist in Mumbai, “Almost every liver cancer patient I’ve treated had a pre-existing liver condition that should have put them into a screening programme years before the cancer showed up, and the ones who were being screened are the ones we caught early enough to actually do something about while the ones who weren’t are the ones who walked in too late.” What are the main risk factors? Most of these have been parked in the medical textbooks for decades and none of them surprise any gastroenterologist who’s been doing this long enough, but what’s genuinely maddening is how many patients carrying them have never once been told they need screening until a tumour shows up and suddenly everyone’s scrambling. Chronic hepatitis B: Single biggest risk factor globally because this virus digs itself directly into liver cell DNA and can trigger cancer even without cirrhosis ever developing along the way, which is why every chronic hep B patient needs six-monthly ultrasound and AFP from day one regardless of how healthy the liver looks on paper or how fine the patient feels. Chronic hepatitis C: Drives cancer risk through the cirrhosis route where years of relentless inflammation stack fibrosis on top of fibrosis until the liver tips into cirrhosis and that’s what sets the stage for cancer, and even though hep C is now curable patients who already had cirrhosis before clearing the virus still carry elevated risk because getting rid of the bug doesn’t fully wind the clock back. Cirrhosis from any cause: Doesn’t matter whether it came from booze, viral hepatitis, fatty liver, autoimmune disease, or something rarer, once cirrhosis has set up shop the cancer risk climbs and stays climbed permanently which is why cirrhosis itself is the single loudest alarm bell that screening needs to be happening every six months no exceptions. Heavy alcohol use: Alcohol batters the liver progressively and years of heavy drinking grind through fibrosis into cirrhosis which then opens the door to cancer, and the damage doesn’t need to be dramatic because patients who’ve been putting away drinks for decades can be sitting on cirrhosis they’ve never been told about until a scan or a cancer forces it into the open. If you carry any of these risk factors, our liver cancer treatment page covers the full screening and treatment pathway from early detection through intervention depending on what gets found. What other factors shove the risk even higher? Beyond the big four there are additional factors that stack on top and push things further, and patients juggling multiple risk factors at once are the ones who need the most aggressive watching because their odds aren’t adding up politely they’re multiplying. Fatty liver disease: NAFLD and especially NASH with fibrosis is racing up the charts as a liver cancer cause globally as obesity and diabetes numbers keep ballooning, and the particularly nasty twist is that some NAFLD patients develop cancer before even reaching cirrhosis which smashes the old assumption that cancer only ever comes after the liver has gone cirrhotic first. Diabetes and obesity: Both independently jack up liver cancer risk beyond what the fatty liver connection alone would account for, and carrying type 2 diabetes alongside significant obesity puts someone at meaningfully higher risk than having just one of those which is why metabolic health matters for liver cancer prevention not just heart disease and not just fatty liver. Aflatoxin exposure: Toxin from mould growing on improperly stored grains and nuts that hits particularly hard in parts of Asia and Africa, and when aflatoxin exposure stacks on top of chronic hepatitis B the cancer risk doesn’t just go up it multiplies which is why food storage practices actually matter for liver cancer prevention in certain parts of the world even though most patients never think about it. Family history: First-degree relative with liver cancer pushes risk up even after accounting for shared hepatitis or shared lifestyle which points to a genetic piece nobody fully understands yet, but it’s strong enough that family history needs to be part of every risk conversation rather than being treated as an afterthought. Understanding how cirrhosis connects to cancer risk helps put the screening conversation in context, and our can liver cirrhosis be reversed blog covers whether catching cirrhosis early enough can change the liver’s trajectory and potentially dial down the cancer risk that comes packaged with it. Why choose Dr. Vipulroy Rathod for liver cancer risk assessment? Dr. Vipulroy Rathod has over 30 years in gastroenterology and hepatology with more than 80,000 endoscopic procedures behind him, and liver cancer risk stratification specifically is one of those areas where the gastroenterologist’s ability to look at a patient’s full metabolic and liver story and correctly sort who genuinely needs aggressive screening from who can be watched more casually is what keeps cancers from growing silently in patients who should’ve been caught way earlier. What patients get here is a risk assessment that refuses to treat everyone the same way, because a cirrhotic with active hep B and diabetes piled on top needs a completely different surveillance game plan than a grade 1 fatty liver patient with zero fibrosis, and stuffing both into the same generic protocol is exactly the kind of lazy shortcut that lets cancers sneak past in the patients sitting at the very top of the risk pile.   Book your consultation today with one of India’s most experienced specialists for liver cancer risk assessment. Book Appointment Call now Frequently Asked Questions Who is most at risk for liver cancer? People with chronic hep B or C, cirrhosis from

Liver cancer treatment in India has advanced significantly with options now ranging from surgical resection and liver transplant to minimally invasive approaches like ablation, TACE, and targeted therapy. Which treatment fits depends entirely on the tumour stage, liver function, and overall health of the patient, and the best outcomes happen when the right option gets matched to the right case rather than defaulting to whatever’s most familiar. According to Dr. Vipulroy Rathod, an experienced Gastroenterologist in Mumbai, “India now offers virtually every liver cancer treatment that’s available anywhere in the world, and the challenge isn’t access to options anymore but making sure each patient gets matched to the treatment that actually fits their specific tumour stage and liver reserve rather than being squeezed into a one-size approach that doesn’t account for the full picture.” What treatment options exist for liver cancer in India? The toolbox has genuinely expanded over the last decade and patients here now have access to the same stuff top centres globally are using, though having all the tools means nothing if the person choosing which one to pick doesn’t understand when each one actually makes sense. Surgical resection: Cutting the tumour out with a margin of healthy liver is the go-to when the cancer is sitting in one spot and the rest of the liver is healthy enough to regenerate and pick up the slack, and this works best in patients without cirrhosis or with well-compensated cirrhosis where the organ can handle losing a chunk without the whole thing falling over. Liver transplant: Swaps out the entire diseased liver for a healthy one which simultaneously wipes out both the cancer and whatever liver disease was underneath it, and India has become a major hub for living-donor transplants where a family member gives part of their liver and both sides grow back within weeks which still blows most patients’ minds when they hear it. Ablation: Heat-based techniques like radiofrequency and microwave ablation that cook small tumours from the inside using a needle poked in through the skin or during surgery, ideal for cancers under 3 cm where the tumour is too small to justify cracking someone open but too dodgy to just sit on and hope it behaves itself. TACE and TARE: TACE pumps chemo directly into the tumour’s blood supply while choking off the artery feeding it, TARE does the same trick but with radioactive beads instead of chemo, and both get used for intermediate cancers that have outgrown ablation but haven’t spread outside the liver yet so surgery isn’t off the table entirely but isn’t the first move either. If you’ve been told you have liver cancer and want to see the full treatment pathway laid out, our liver cancer treatment page covers every option depending on stage and what shape the liver is in underneath. How does the treatment decision actually get made? Nobody picks treatment by just eyeballing the tumour because the liver it’s growing in matters just as much if not more, and getting this call wrong either way means either undertreating something that was curable or bulldozing a patient whose liver couldn’t handle what got thrown at it. Tumour staging: Size, how many tumours are present, whether cancer has burrowed into blood vessels, and whether it’s jumped outside the liver all feed into a staging system that narrows the options down fast, because a lonely 2 cm nodule and a multifocal cancer that’s invaded the portal vein are living in completely different treatment universes. Liver function reserve: A patient with a solid healthy liver can sail through a resection that would absolutely wreck a patient with decompensated cirrhosis, which is why liver function scoring using Child-Pugh and MELD matters just as much as the cancer staging and sometimes it’s the liver not the tumour that yanks surgery off the table. Tumour board discussion: Best results happen when the case gets thrown in front of a hepatologist, liver surgeon, interventional radiologist, and oncologist all sitting in the same room rather than one specialist making the call solo, because liver cancer parks itself at the intersection of multiple specialties and any plan built without input from all of them has blind spots. The patient in the room: Age, other health problems, willingness to go through major surgery versus lighter options, and whether proper follow-up is realistically going to happen all factor in, because the technically perfect treatment on paper isn’t always the right treatment for the actual human being sitting across the desk who has to live with whatever gets decided. Catching liver cancer early enough for these treatments to work is the whole ballgame, and our how liver cancer is diagnosed with EUS blog covers how endoscopic ultrasound plays a role in nailing down suspicious liver lesions that standard imaging can spot but can’t characterise well enough to confidently act on. Why choose Dr. Vipulroy Rathod for liver cancer evaluation? Dr. Vipulroy Rathod has over 30 years in gastroenterology and hepatology with more than 80,000 endoscopic procedures behind him, and liver cancer specifically needs someone who understands the tumour and the liver it’s sitting in equally well because the treatment decision hangs on both and a gastroenterologist with deep hepatology chops is often the person best positioned to call whether the liver can actually survive what the surgeon or oncologist is planning to put it through. What patients get here is a staging workup that feeds into a proper multidisciplinary conversation rather than one specialist deciding in a vacuum, because liver cancer is one of those diseases where picking the right treatment through the wrong process can still blow up in everyone’s face and the pathway to the decision matters just as much as the decision itself. Book your consultation today with one of India’s most experienced specialists for liver cancer evaluation. Book Appointment Call now Frequently Asked Questions What are the main liver cancer treatments in India? Surgical resection, transplant, ablation, TACE, TARE, targeted therapy, and immunotherapy are all available

Endoscopic ultrasound or EUS diagnoses liver cancer by getting an ultrasound probe right up against the stomach wall millimetres from the liver, giving far sharper images than a regular abdominal ultrasound and allowing the gastroenterologist to take tissue samples through fine needle biopsy in the same sitting. This combination of high-resolution imaging and immediate biopsy capability is what makes EUS invaluable for liver lesions that standard scans can see but can’t characterise well enough to confirm whether they’re cancerous or not. According to Dr. Vipulroy Rathod, an experienced Gastroenterologist in Mumbai, “EUS changed how we approach suspicious liver lesions because instead of sending patients through multiple rounds of imaging and then a separate interventional radiology appointment for biopsy we can now see the lesion in detail and sample it in one procedure, which saves weeks of diagnostic delay that patients with potential liver cancer simply can’t afford.” How does EUS work for diagnosing liver cancer? Regular imaging spots the lesion but EUS gets close enough to actually interrogate it, and that proximity is what separates a report that says “suspicious mass needs further investigation” from one that gives a definitive answer about what the mass actually is. Proximity advantage: The ultrasound probe sits inside the stomach or duodenum right next to the liver with no fat, muscle, or bowel gas in between to degrade the image, which is why EUS picks up details in liver lesions that a regular abdominal ultrasound scanning through layers of belly wall simply can’t resolve no matter how good the machine is. Fine needle biopsy: Once the gastroenterologist sees the lesion clearly on EUS they can pass a needle through the stomach wall directly into the mass under real-time ultrasound guidance, pull out tissue or fluid, and send it to pathology for a definitive answer about whether it’s hepatocellular carcinoma, a metastasis from somewhere else, or something benign that doesn’t need treatment at all. Small lesion detection: EUS catches liver lesions as small as 5 to 10 mm that CT and MRI sometimes miss or can’t characterise properly, and in patients being surveilled for liver cancer where catching a tumour at 1 cm versus 3 cm is the difference between a curable stage and a complicated one that level of sensitivity genuinely matters. Vascular assessment: EUS with doppler shows blood flow patterns within and around the lesion which helps distinguish between different types of liver masses because hepatocellular carcinoma has a characteristic blood supply pattern that benign lesions and metastatic deposits don’t share, adding another layer of diagnostic confidence before the biopsy needle even goes in. If you want to understand EUS as a procedure beyond just liver applications, our endoscopic ultrasound page covers the full range of conditions EUS investigates and what patients can expect during and after the procedure. When is EUS better than CT or MRI for liver cancer? CT and MRI are the workhorses for liver imaging and nobody’s arguing against that, but there are specific situations where EUS adds something those scans physically can’t provide and knowing when to reach for it versus when standard imaging is enough is part of what separates a thorough workup from a superficial one. Indeterminate lesions: When CT or MRI finds a liver mass but can’t definitively say whether it’s cancer, a benign nodule, or something else entirely, EUS with biopsy settles the question with tissue rather than leaving everyone guessing and scheduling yet another scan in three months to see if it’s grown. Biopsy without percutaneous access: Some liver lesions sit in spots that are difficult or risky to reach with a needle through the skin because of overlying bowel, lung, or blood vessels in the way, and EUS offers an alternative biopsy route through the stomach wall that avoids those obstacles entirely. Staging completeness: EUS can assess not just the liver mass itself but also check for regional lymph node involvement, evaluate the portal vein for tumour invasion, and look at surrounding structures all in one sitting, which gives staging information that sometimes changes the surgical plan before the patient ever reaches the operating room. Surveillance in high-risk patients: For patients with cirrhosis where the liver is already nodular and difficult to read on standard imaging, EUS provides clearer characterisation of new or changing nodules that might be early HCC developing against a background of cirrhotic changes that make regular ultrasound interpretation unreliable. Understanding how liver cancer gets caught early puts the EUS role in proper context, and our early signs of liver cancer blog covers what warning signs to watch for and why screening matters so much for catching tumours while they’re still at a stage where EUS-guided biopsy and curative treatment are realistic options. Why choose Dr. Vipulroy Rathod for EUS liver cancer diagnosis? Dr. Vipulroy Rathod has over 30 years in advanced gastroenterology with more than 80,000 endoscopic procedures behind him, and EUS-guided liver biopsy specifically is one of those procedures where the operator’s hands and judgment directly determine whether the needle hits the lesion cleanly on the first pass or whether the patient ends up needing repeat procedures because the sample wasn’t adequate, and that gap between a high-volume EUS operator and someone who does these occasionally shows up directly in diagnostic accuracy. What patients get here is EUS done by someone who’s performed enough of these to know which lesions need tissue and which ones can be confidently called on imaging alone, because not every liver mass needs a needle in it and the skill isn’t just in doing the biopsy well but in knowing when doing one is genuinely necessary versus when the imaging already has the answer and poking it would just be adding risk for no additional information. Book your consultation today with one of India’s most experienced specialists for EUS liver evaluation. Book Appointment Call now Frequently Asked Questions What is EUS and how does it diagnose liver cancer? EUS places an ultrasound probe inside the stomach right next to the liver

Early signs of liver cancer are often mild or absent, but key warning signs include unexplained weight loss, loss of appetite, upper right abdominal pain, persistent fatigue, and nausea. Other early indicators include jaundice with yellowing skin and eyes, abdominal swelling, easy bruising, and a hard lump under the ribs. Promptly checking these symptoms is crucial. According to Dr. Vipulroy Rathod, an experienced Gastroenterologist in Mumbai, “The patients who get diagnosed with liver cancer early are almost never the ones who noticed symptoms first, they’re the ones who were already being screened because of a known risk factor, and that’s the whole argument for surveillance in high-risk groups rather than waiting for the body to wave a red flag it usually waves too late.” What does early liver cancer actually look like? Most of these signals on their own could mean absolutely anything which is what makes catching liver cancer early such a nightmare, but when they pop up in someone already carrying liver disease or known risk factors the alarm needs to go off immediately rather than getting blamed on stress or bad food or getting older. Weight dropping for no reason: Losing kilos without trying is one of the first things the body does when something metabolically ugly is brewing inside, and while weight loss alone doesn’t point straight at cancer it becomes a lot scarier when it shows up in a patient with cirrhosis or chronic hepatitis whose weight has been rock steady for years. Dull ache under the right ribs: Not a sharp come-and-go pain like gas but a persistent heaviness that parks itself in the upper right belly and refuses to leave, and patients routinely chalk it up to pulled muscles or work stress for months before someone finally images the area and spots something sitting there that has no business being there. Appetite vanishing: Feeling full after a few bites or losing all interest in eating, usually because a growing mass inside the liver or the organ swelling up starts squashing the stomach and stealing the space food normally goes into, and patients blame their age or mood or busy schedule for ages before the liver enters the conversation. Bone-deep exhaustion: Not normal end-of-day tiredness but a heavy dragging fatigue that rest doesn’t touch and sleep doesn’t fix, and when it turns up alongside other quiet changes like appetite tanking or weight shifting in someone with known liver disease it needs investigating rather than getting written off as just running on empty. If you carry risk factors and want to know what screening and treatment look like, our liver cancer treatment page covers the full pathway from surveillance through intervention depending on what stage things are at when they get found. Why does it get missed until it’s too late? The liver is a stupidly forgiving organ that keeps compensating until it physically can’t anymore, which means a tumour can sit inside it growing for months without producing a single clue that would make anyone suspect cancer is in the building. Silent organ: No pain receptors inside the liver tissue itself so a mass can balloon up significantly before it stretches the outer capsule enough to actually hurt, which is why patients with small early tumours feel absolutely nothing and have zero reason to walk into a clinic unless screening drags them in first. Symptoms hide behind existing disease: Patients who already live with cirrhosis or hepatitis deal with fatigue, belly discomfort, and appetite changes as their normal baseline, so when a cancer starts piling its own symptoms on top those additions just blend into the existing noise rather than standing out as something new and separate. Screening doesn’t reach enough people: High-risk patients are supposed to get six-monthly ultrasound and AFP but a huge number either don’t know they qualify, never get told by their doctor, or skip appointments because they feel fine, and that gap between who should be screened and who actually is being screened is precisely where the late diagnoses keep coming from. AFP plays tricks: Alpha-fetoprotein is the blood marker everyone relies on for liver cancer screening but not every tumour produces it, meaning some cancers grow with a perfectly normal AFP that gives everyone a false sense of security if nobody’s running imaging alongside it to catch what the blood test missed. Getting the viral hepatitis angle right matters because both hep B and C raise cancer risk through different routes, and our hepatitis B vs hepatitis C blog covers how each virus drives liver damage differently and why the screening protocol can’t just be the same for both Why choose Dr. Vipulroy Rathod for liver cancer screening? Dr. Vipulroy Rathod has over 30 years in gastroenterology and hepatology with more than 80,000 endoscopic procedures behind him including heavy EUS work evaluating liver masses, and liver cancer screening is one of those areas where having someone who knows what a 1 cm hepatocellular carcinoma looks like on imaging versus what it doesn’t look like is literally the gap between catching something curable and finding something that’s already moved past the point where a cure is still on the table. What patients get here is surveillance built around their actual risk profile rather than a one-size-fits-all scan schedule, because a cirrhotic with hep B needs different monitoring intensity than a fatty liver patient with no fibrosis and lumping everyone into the same protocol is exactly how cancers slip through the net in patients who deserved better attention from the start. Book your consultation today with one of India’s most experienced specialists for liver cancer screening. Book Appointment Call now Frequently Asked Questions Does liver cancer show early symptoms? Rarely, since most early cases get caught through screening rather than symptoms, and by the time signs like weight loss or belly pain become noticeable the cancer has usually already grown past the stage where the easiest treatment options are still available. Who needs liver cancer screening? Anyone with cirrhosis,

Fatty liver and high cholesterol are tightly linked because both stem from the same metabolic dysfunction where the body mishandles fats. High cholesterol, especially elevated triglycerides and low HDL, both feeds fat into the liver and gets worse when the liver is already fatty, creating a loop where each condition keeps making the other harder to control. According to Dr. Vipulroy Rathod, an experienced Gastroenterologist in Mumbai, “Patients often get told their cholesterol is high and their liver is fatty as if those are two separate problems being managed by two different doctors, but they’re really two faces of the same metabolic mess and treating one without addressing the other is why so many patients stay stuck despite being on medication for years.” How do fatty liver and high cholesterol feed into each other? They don’t just coexist by coincidence, they actively make each other worse through a metabolic loop that keeps spinning until someone addresses the root cause driving both of them at the same time rather than chasing each one separately. Liver makes cholesterol: The liver is where most of the body’s cholesterol gets manufactured and when the organ is packed with fat that production goes into overdrive, pumping out more VLDL particles loaded with triglycerides which is why fatty liver patients often have lipid panels that look terrible even when their diet isn’t particularly bad. High triglycerides dump fat into the liver: Elevated triglycerides in the blood mean more fat circulating that the liver has to process and store, and when the incoming load exceeds what the organ can export or burn off the excess just keeps piling up inside the liver cells making the fatty liver progressively worse over time. Insulin resistance ties them together: The metabolic thread connecting both conditions is usually insulin resistance where cells stop responding to insulin properly, the liver ramps up both fat storage and cholesterol production simultaneously, and the patient ends up with a fatty liver and a bad lipid profile that are really just two symptoms of the same underlying problem. Inflammation multiplies the damage: Once fatty liver tips into NASH the chronic inflammation doesn’t stay confined to the liver because it spills inflammatory markers into the bloodstream that accelerate atherosclerosis in the arteries, which means a patient with NASH and high cholesterol is carrying cardiovascular risk that’s significantly higher than either condition would pose on its own. If your liver has been flagged as fatty alongside abnormal cholesterol levels, our fatty liver treatment page covers how the metabolic drivers behind both conditions get addressed through a management approach that tackles the liver and the lipids together rather than treating them as separate problems. What should patients with both conditions know about treatment? Managing one while ignoring the other is how patients end up on statins for years with a liver that keeps getting fattier in the background, which is why the treatment approach needs to hit the shared root cause rather than putting band-aids on each symptom individually. Weight loss fixes both: Losing 7 to 10 percent of body weight reduces liver fat and improves cholesterol numbers simultaneously because it addresses the insulin resistance and metabolic dysfunction sitting underneath both conditions, and this is one of the rare situations in medicine where a single intervention genuinely tackles two problems at once. Statins are safe with fatty liver: A lot of patients and some doctors worry about using statins when the liver is fatty because of the liver enzyme association, but the evidence is clear that statins are not only safe in NAFLD but actually beneficial because they reduce cardiovascular risk which is the leading cause of death in fatty liver patients, not the liver disease itself. Diet quality over calorie counting: Swapping processed carbs and sugary foods for whole grains, vegetables, lean protein, and healthy fats like olive oil and nuts improves both the liver and the lipid panel because it changes the metabolic inputs the body is working with rather than just restricting how much goes in. Exercise independently helps both: Regular physical activity reduces liver fat and improves cholesterol even without weight loss on the scale, because exercise changes how the body processes lipids and responds to insulin at a cellular level which is why a patient who starts moving regularly often sees their numbers improve before the scale budges even a kilo. Understanding how fatty liver connects to other metabolic conditions puts the cholesterol link in broader perspective, and our fatty liver and diabetes blog covers another major metabolic overlap where the same insulin resistance driving fatty liver and bad cholesterol also pushes blood sugar in the wrong direction. Why choose Dr. Vipulroy Rathod for fatty liver and metabolic evaluation? Dr. Vipulroy Rathod has over 30 years in gastroenterology and hepatology with more than 80,000 procedures behind him, and metabolic liver disease is a core part of how this clinic operates because fatty liver patients almost always walk in carrying cholesterol problems, blood sugar issues, or both, and managing the liver without addressing the full metabolic picture is exactly how patients end up being treated by three different specialists who aren’t talking to each other. What patients notice here is that the liver, the lipids, and the metabolic risk factors all get evaluated as one connected problem rather than being split into separate departments with separate plans, because the gastroenterologist who understands how fatty liver drives cholesterol and how cholesterol drives liver damage is the one best positioned to build a plan that actually moves all the numbers in the right direction at the same time. Book your consultation today with one of India’s most experienced specialists for fatty liver and metabolic liver evaluation. Book Appointment Call now Frequently Asked Questions Does fatty liver cause high cholesterol? Fatty liver ramps up cholesterol production in the liver itself which worsens lipid levels, while high cholesterol simultaneously dumps more fat into the liver making the fatty liver worse, so they feed each other in a loop.

Fatty liver is typically diagnosed through a combination of blood tests like liver function panels, abdominal imaging such as ultrasound, CT, or MRI, and specialised tests like FibroScan to measure liver fat and stiffness. Often it gets discovered during routine tests for other conditions since it rarely presents early symptoms. According to Dr. Vipulroy Rathod, an experienced Gastroenterologist in Mumbai, “Finding fat on an ultrasound is the easy part, what takes real clinical judgment is working out whether that fat has tipped into NASH and whether fibrosis has already started, because those two questions are what decide the entire management plan and most patients never get them answered at their first appointment.” What tests pick up fatty liver? Diagnosis usually kicks off with something simple and cheap that catches the fat, then gets layered with more specific tools depending on how much detail the gastroenterologist needs to figure out whether the liver is actually in trouble or just lugging around extra baggage it doesn’t want. Ultrasound: First thing that catches fatty liver in most patients because the liver glows brighter than the kidney when fat is present, takes minutes, costs next to nothing, and usually gets done for a completely unrelated reason like a gallbladder check which is how the whole fatty liver conversation accidentally gets kicked off. Liver enzymes: ALT and AST being elevated on routine blood work is often the first red flag that sends a doctor reaching for an ultrasound order, though plenty of fatty liver patients have completely normal enzymes which is why normal blood work on its own doesn’t rule anything out and imaging still needs to happen when risk factors are sitting there. Metabolic workup: Triglycerides, cholesterol, fasting glucose, and HbA1c fill in the metabolic picture because fatty liver almost never shows up alone and knowing which metabolic levers are pulled in the wrong direction helps guide treatment since fixing the liver without fixing the metabolism behind it is like mopping while the tap’s still running. Hepatitis screening: Ruling out hep B and C is standard because viral hepatitis can cause the exact same enzyme bumps and sometimes rides alongside fatty liver, and you need to know whether a virus or booze is contributing before blaming everything on metabolic causes and calling it a day. If fatty liver has already been flagged on a scan, our fatty liver treatment page covers the full management approach from lifestyle overhaul through medical monitoring depending on what the complete workup actually shows. How do doctors tell if the fat is doing damage? Spotting the fat is step one but the question that actually matters is whether it’s causing harm underneath, because a liver stuffed with fat that isn’t inflamed is a completely different beast from one where NASH is actively chewing through tissue and laying down scar. Fibroscan: Fires a pulse through the liver and measures stiffness, with stiffer readings meaning more fibrosis, and this has basically taken over from liver biopsy for most patients because it’s quick, painless, done right in clinic, and spits out a number the gastroenterologist can track over time to see whether things are holding or creeping the wrong way. FIB-4 and NFS scores: Blood-based calculations using age, platelets, ALT, AST, and BMI that estimate fibrosis risk without needing any imaging at all, and while they’re not as sharp as fibroscan they’re free, built from routine blood work most patients already have, and excellent at sorting people into “probably fine” versus “needs a closer look” buckets. Liver biopsy: Still the gold standard for seeing inflammation, fibrosis staging, and fat distribution under a microscope, but it’s invasive with a small bleeding risk so it gets saved for cases where fibroscan and blood scores can’t agree on an answer or when the gastroenterologist genuinely needs tissue-level detail that nothing else can provide. MRI-PDFF: Measures liver fat percentage with extreme precision and shows up more in research and specialist centres, though it’s pricey and not widely available for routine clinic use which means most patients get diagnosed and tracked perfectly well with ultrasound and fibroscan without ever needing to go anywhere near an MRI machine. Understanding what the ultrasound grades mean helps put these diagnostic findings in proper context, and our fatty liver grade 1 vs 2 vs 3 blog breaks down what those grade numbers actually tell you versus what they leave out and why the grade alone is never enough to build a management plan around. Why choose Dr. Vipulroy Rathod for fatty liver diagnosis? Dr. Vipulroy Rathod has over 30 years in gastroenterology and hepatology with more than 80,000 procedures behind him, and fatty liver diagnosis is one of those areas where the gap between a thorough evaluation and a rushed one shows up years down the line because the patients who got properly assessed upfront are the ones whose livers got caught and managed early while the ones who just got a grade number and a handshake are the ones who drifted until things had already gone further than they ever needed to. What patients get here isn’t a scan result and a “come back if it gets worse” dismissal but a layered workup that answers whether the fat is harmless or actively damaging, whether fibrosis has started setting up shop, and which specific metabolic factors are feeding the problem, because those answers are exactly what turn a vague fatty liver label into something the patient and doctor can actually act on together. Book your consultation today with one of India’s most experienced specialists for fatty liver evaluation. Book Appointment Call now Frequently Asked Questions How is fatty liver usually found? Most cases get caught accidentally on an ultrasound or blood test done for something else, since early fatty liver causes no symptoms and patients have no clue anything is off until it shows up by surprise. Can blood tests alone diagnose fatty liver? Elevated enzymes raise suspicion but can’t confirm it on their own because plenty of fatty liver

Fatty liver gets graded based on how much fat has accumulated inside the liver on ultrasound, with grade 1 being mild, grade 2 moderate, and grade 3 severe. The grade alone doesn’t tell the full story because what actually matters is whether that fat is causing inflammation and fibrosis underneath, but knowing your grade gives both you and your gastroenterologist a starting point for deciding how aggressively things need to be monitored and managed. According to Dr. Vipulroy Rathod, an experienced Gastroenterologist in Mumbai, “Patients fixate on the grade number they see on their ultrasound report but the grade itself doesn’t tell you whether the liver is in trouble or just carrying extra fat quietly, which is why the workup can’t stop at an ultrasound and needs to include fibrosis assessment before anyone can say what that grade actually means for the patient sitting in front of them.” What do the three grades actually mean? Ultrasound grades fatty liver by comparing how bright the liver looks next to the kidney, and the brighter it glows the more fat is stuffed inside, but here’s what most patients don’t realise, two radiologists staring at the exact same scan can sometimes argue over whether it’s a 1 or a 2 because this grading system is genuinely rough around the edges. Grade 1 — Mild: Bit of extra fat making the liver slightly brighter than the kidney, usually zero symptoms, blood tests often look perfectly normal, and the honest truth is that most patients at this level will never have a single liver problem from it as long as the metabolic stuff underneath doesn’t keep sliding in the wrong direction. Grade 2 — Moderate: Noticeably more fat with the liver glowing brighter and deeper structures starting to look fuzzy on the scan, enzymes may or may not be acting up, and this is typically the grade where a good gastroenterologist starts leaning in harder because the hop from grade 2 into NASH and early fibrosis territory is where things can go from boring to clinically worrying. Grade 3 — Severe: Liver is so loaded with fat it lights up like a torch and the blood vessels and diaphragm behind it basically vanish on ultrasound, often paired with elevated enzymes and complaints like dragging fatigue and upper belly heaviness, and patients here need fibroscan or equivalent because the odds of NASH and scarring already being underway are high enough that just assuming it’s fine would be reckless. Grade ≠ damage: A grade 1 patient with active NASH quietly eating away at the liver is in worse shape than a grade 3 patient whose liver is packed with fat but completely unbothered by inflammation, which is exactly why the number on the ultrasound report can’t be the end of the conversation and fibrosis testing needs to fill in what the grade leaves out. If ultrasound has flagged fatty liver at any grade, our fatty liver treatment page covers what management looks like from lifestyle overhaul through proper monitoring depending on what the full picture actually shows once you look past just the grade. Does the grade decide how serious things are? Not really and this is where most patients and honestly a fair chunk of doctors get it backwards, because the grade tells you how much fat is parked in the liver but says absolutely zero about whether that fat has started wrecking the place or is just sitting there minding its own business. Fibrosis trumps grade: Fibroscan or a FIB-4 blood score paints a far more honest picture of liver health than the ultrasound grade ever could, because fibrosis is what actually marches toward cirrhosis and failure while fat on its own mostly just hangs around looking bad on a scan without necessarily breaking anything. NASH is the actual problem: Whether NASH is present or absent is what sorts fatty liver patients into the “relax and keep an eye on it” bucket versus the “get on top of this now before it gets away from you” bucket, and NASH can show up at any grade which is why a grade 1 patient with inflammation is a bigger concern than a grade 3 patient whose liver is fatty but perfectly chill. Lifestyle works at every level: Dropping 7 to 10 percent of body weight pulls fat out of the liver whether you started at grade 1 or grade 3, and patients who genuinely commit to sustained eating changes and regular movement often watch their grade fall on the next ultrasound within 6 to 12 months which is one of the few spots in medicine where effort shows up directly on a scan. When to actually worry: Grade 3 paired with enzymes climbing, fibroscan scores creeping up, or symptoms like bone-deep tiredness and belly discomfort that won’t shift needs proper aggressive follow-up because the chances of NASH and fibrosis already being baked in at that point are too high to just shrug off and wait for next year’s annual scan. Seeing where fatty liver can end up if it goes unchecked puts the grading in perspective, and our can fatty liver cause liver failure blog covers the full progression from harmless fat through NASH to cirrhosis and spells out exactly where things cross from manageable into genuinely dangerous territory. Why choose Dr. Vipulroy Rathod for fatty liver grading and evaluation? Dr. Vipulroy Rathod has over 30 years in gastroenterology and hepatology with more than 80,000 procedures behind him, and fatty liver evaluation goes way beyond just reading a grade off an ultrasound because the real work is correlating that number with fibroscan results, blood markers, metabolic risk factors, and clinical history to build a picture that actually tells you whether this liver needs someone paying close attention or whether it’s genuinely fine to leave it alone for now. What patients notice here is that nobody walks out clutching just a grade number and a generic “clean up your diet” pamphlet, because the evaluation digs deep enough